Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study

Tejpar, Sabine; Peeters, M; Gelderblom, H; Humblet, Y; Vermorken, J; De Hertogh, G; Nippgen, J; von Heydebreck, A; Stroh, C; Van Cutsem, Eric

Annals of oncology

Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study

Author:

Tejpar, Sabine

Peeters, M ; Gelderblom, H ; Humblet, Y ; Vermorken, J ; De Hertogh, G ; Nippgen, J ; von Heydebreck, A ; Stroh, C ; Van Cutsem, Eric

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Annals of oncology Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study

Author:

Keywords:

Annals of oncology

Relationship of efficacy with kras status (wild type [wt] vs mutant [mt]) in patients with irinotecan-refractory metastatic colorectal cancer (mcrc), treated with irinotecan and escalating doses of cetuximab: preliminary data from the everest study